Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.
Second Department of Internal Medicine, Toyama University, Toyama, Japan.
J Cardiol. 2019 Feb;73(2):102-107. doi: 10.1016/j.jjcc.2018.10.003. Epub 2018 Nov 9.
One of the vasopressin type 2 receptor antagonists, tolvaptan, has been used to treat congestive heart failure patients for over seven years in Japan. Beyond the initially suggested standard procedure, tolvaptan is currently used in patients with acute heart failure soon after their admission or it is used for long-term treatment in the ambulatory situation. Nevertheless, definitive evidence is lacking, particularly for the implication of long-term tolvaptan therapy. Now is the time to update the accumulating evidence and consider the optimal therapeutic strategy for short- and long-term tolvaptan therapy.
一种血管加压素 2 型受体拮抗剂，托伐普坦，在日本已经被用于治疗充血性心力衰竭患者超过七年。除了最初建议的标准程序外，托伐普坦目前在急性心力衰竭患者入院后不久即被使用，或在门诊情况下用于长期治疗。然而，目前仍然缺乏明确的证据，特别是对于长期托伐普坦治疗的影响。现在是时候更新累积的证据，并考虑短期和长期托伐普坦治疗的最佳治疗策略。
